Section 1: Company Overview and Fundamentals

Company Overview:

Novo Nordisk A/S (NYSE: NVO) is a global healthcare company that develops, manufactures and markets medicines for diabetes, obesity and rare diseases. Its products include insulin, GLP-1 therapies, oral diabetes and obesity treatments, and medicines for haemophilia, growth disorders and hormone replacement. The company operates across North America and international markets.

Kalkine’s Low Carbon Research Report covers the Investment Highlights, Low Carbon Emission Initiatives, Key Financial Metrics, Risks, and Technical Analysis along with the Valuation, Target Price, and Recommendation on the stock.

Past performance is not a reliable indicator of future performance.